We selected miRNAs for each of SMAD4 (hsa-miR-421 and hsa-miR-454-3p) and PTEN (hsa-miR-107 and hsa-miR-320a-3p) for binding validation since the four miRNAs have been reported to have important association with heart development or congenital heart disease (O’Brien et al., 2012; Zhou et al., 2014; Colpaert and Calore, 2019; Grunert et al., 2019). The gene discussed is SMAD4; the disease is congenital heart disease.